“The efficacy with three doses of Abdala is 92.28%”, confirmed by the scientist Marta Ayala to the First Secretary of the Communist Party of Cuba and President of the Republic Miguel Díaz-Canel Bermúdez. More than a vaccine, it is a country!
Seconds after receiving such pleasant news, the President of Cuba wrote on Twitter: «I think of Martí, who wrote: ” it is not intelligence received and casual that gives a man honor; but the way he uses it and saves it, not there is more than one way to endure and that is to serve. ”And in #Fidel, who said: “everyone who has a vocation for health, I invite you to study … There is a huge world that is in need”
He further added that “Hit by two pandemics (# COVID19 and #Bloqueo), our scientists from Finlay Institute and the CIGB, have jumped over all obstacles and have given us two very effective vaccines: # SOBERANA02 and #Abdala”.
Abdala is named the vaccine candidate created by the Center for Genetic Engineering and Biotechnology (CIGB). It is in phase III of a clinical trial to assess its safety and immunogenicity against SARS-CoV-2. Last Saturday, during a meeting of the Cuban Government with scientists, it was announced that the effectiveness of Soberana 02, in its two doses, is 62%, which exceeds the requirements of the World Health Organization (WHO) for a vaccine candidate against COVID-19 to become a vaccine, which is 50%.
The WHO also recommends that the confidence interval for the analysis of this efficacy exceeds 30%, and Soberana 02 has confidence intervals above 40%, so we can say that we are meeting the two requirements recommended by the Organization to consider a vaccine candidate as an effective vaccine, said Vicente Vérez Bencomo, director of the IFV.
A LITTLE MORE ABOUT ABDALA AND ITS TOUR THROUGH CUBA
On June 3, given the complex epidemiological situation in Havana, it was decided to extend to all its municipalities, starting in the second half of June, the health intervention with the three doses of the vaccine candidate Abdala, which was applied in groups and risk territories of the capital.
The Minister of Public Health, José Angel Portal Miranda, explained that the purpose of this immunization is that, at the end of June, the entire population of Havana scheduled to vaccinate, have applied at least one dose of Abdala, and more than 50%, two doses.
Clinical trials with this candidate, for intramuscular application, began their phase I on December 7, with 132 volunteers, a number that was later expanded to 660 in phase II. In the case of phase III, which began on March 22, the study sample had a larger dimension, since 48,290 people were included who were vaccinated in six weeks, in periods of 0, 14 and 28 days, which required an intense work of the participants.
Some 4,328,291 doses of the vaccine candidates Soberana 02 and Abdala have been administered in Cuba until June 16 as a result of the sum of clinical trials, intervention studies, plus health intervention in risk groups and territories.
The data, reported by Dr. María Elena Soto Entenza, head of the Department of Primary Health Care of the Minsap, during a broadcast on the subject of the television program Mesa Redonda, reveals the way in which “one of the most complex processes that has had the national public health system since its creation. She also informed the specialist that as of June 4, the intervention study with Soberana Plus began in health workers convalescing from covid-19, in the provinces of Havana and Matanzas.
Some 2 145 685 people had received at least one dose, while 1 389 480 had already received the second dose and 793 126 had the third dose, the specialist also detailed, who summarized that until June 17, only as As part of the health intervention, more than 3,500,000 doses had been applied.
Source: CMHW
Views: 0
